The bipartisan Senate AI Task Force Creates an AI policy roadmap for the U.S. Senate and directs the Senate Appropriations Committee to fund cross-government artificial intelligence research and development projects, including biotechnology research and AI applications that fundamentally transform health care. We encourage you to do so.
The Group recognizes a variety of use cases for AI, including in healthcare settings, such as improving the diagnosis of diseases, developing new medicines, and supporting healthcare providers in a variety of capacities.
The senators wrote that relevant committees should consider enacting legislation to support the adoption of AI in this area. Guardrails and safety measures must also be put in place to ensure patient safety while ensuring regulations do not stifle innovation.
“This includes protecting consumers, preventing fraud and abuse, and promoting the use of accurate and representative data,” the senators wrote.
The law should also establish transparency requirements for health care providers and the general public to understand the use of AI in health care products and clinical settings, including information about the data used to train AI models. there is.
In the roadmap, the committee will help the National Institutes of Health (NIH) develop and improve AI technologies, particularly data governance and making data available for scientific and machine learning research while ensuring patient privacy. It states that support should be given to
Health and Human Services (HHS) agencies, such as the Food and Drug Administration (FDA) and the Office of the National Coordinator for Health Information Technology, should also be provided with tools to effectively determine the benefits and risks of AI-enabled products. This allows developers to adhere to a predictable regulatory structure.
The senators said the committee should also consider “policies that encourage innovation in AI systems that meaningfully improve health outcomes and the efficiency of health care delivery, including through the Centers for Medicare and Medicaid Services' reimbursement mechanisms and This should include consideration of guardrails to ensure accountability.” Appropriate use of AI and widespread application across all populations. ”
The group also encouraged companies to conduct rigorous testing to assess and understand the potential harmful effects of AI products and not release products that do not meet industry standards.
bigger trends
During December, Brought to you by Digital Health Leaders Mobi Health News We provide unique insight into how regulators should set rules for the use of AI in healthcare.
“First, regulators must agree on the controls needed to safely and effectively integrate AI into various aspects of healthcare, taking into account risks and good manufacturing practices.” Weldock said. Mobi Health News.
“Second, regulators must go beyond regulation and provide guidelines to industry that allow companies to test and implement in real-world environments. This will support innovation, discovery, and the necessary evolution of AI.” It will help you.”
sales force Amit Khanna, senior vice president and director of health, said regulators also need to define and set clear boundaries around data and privacy.
”Rather than regulations creating walled gardens and silos in the healthcare sector, regulators will ensure that AI can reduce the costs of detection, care delivery, and research and development while minimizing risk. There is a need,” Khanna said.
Google Chief Clinical Officer Dr Michael Howell said: Mobi Health News This means regulators need to think about a hub-and-spoke model.
“We believe that AI is too important to be properly regulated or regulated. We believe that doing so will accelerate innovation, not set it back,” Howell said.
“However, there are some risks: If we end up with a patchwork of regulations that differ meaningfully from state to state or country to country, we are likely to see a setback in innovation. ”